Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.65 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.52 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107396 | 0.97 | — | — | |
| Bromide SCHEMBL31513717 | 0.94 | MAOB (0.61) | MAOBTAAR1HRH3IDO1AGXT | |
| Iodide SCHEMBL29120576 | 0.94 | MAOB (0.61) | MAOBTAAR1HRH3IDO1AGXT | |
| Methane SCHEMBL10521618 | 0.94 | MAOB (0.61) | MAOBTAAR1HRH3IDO1AGXT | |
| Ammonia Solution, Strong SCHEMBL9177329 | 0.94 | MAOB (0.61) | MAOBTAAR1HRH3IDO1AGXT | |
| Hydrochloric Acid SCHEMBL2069798 | 0.92 | HRH3 (0.70) | MAOBTAAR1HRH3IDO1AGXT | |
| SCHEMBL2092888 | 0.89 | HRH3 (0.74) | MAOBTAAR1HRH3IDO1AGXT | |
| Methyl Alcohol SCHEMBL27971747 | 0.89 | MAOB (0.57) | MAOBTAAR1HRH3IDO1AGXT | |
| SCHEMBL28416493 | 0.87 | MAOB (0.55) | MAOBTAAR1HRH3IDO1AGXT | |
| Hydrochloric Acid SCHEMBL6159403 | 0.86 | MAOB (0.69) | MAOBTAAR1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118530297-A | Ketone amide compound, preparation method and application thereof | 四川大学 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-2638002-B1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER IP GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| CN-103804108-A | Method for preparing primary amine | UNIV SHENYANG PHARMACEUTICAL | 2014-05-21 | — | — | CN | disclosed |
| EP-2638002-A1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-8450528-B2 | Process for the preparation of 2,2-difluoroethylamine starting from a benzylamine compound | BAYER CROPSCIENCE AG (DE) | 2013-05-28 | — | — | US | disclosed |
| WO-2012062702-A1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER CROPSCIENCE AG (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-1993015056-A1 | PYRIDONE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| US-5098900-A | Reducing contractions in smooth muscles | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| EP-0201765-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4892947-A | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0201765-A2 | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-20 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-4148625-A | Tetrahydroisophthalimide compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | MAOB 2731/4885HRH3 740/4885SLC6A2 3449/4885 |
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | HDHD5, CTRB2, H1-2 | MAOB 756/4885HRH3 21/4885SLC6A2 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.